Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide
JACC: Advances · 2026-12 · 5 (12) · 103402
DOI: 10.1016/j.jacadv.2026.103402 ↗Kurz gefasst
Leserbrief in der Zeitschrift JACC: Advances, 2026-12. Verfasst von Jianghe Yan und 1 weiteren Autor:innen. Beteiligte Einrichtung: The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methodological ConcernsWe read with great interest the target trial emulation study by Azzam et al 1 comparing cardiovascular and cerebrovascular outcomes between semaglutide and tirzepatide.However, several methodological aspects of this study merit further clarification.
Autor:innen und Institutionen
- The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China.
- The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. Electronic address: guangtingzeng2025@163.com.
Zitieren
APA
Yan, J., & Zeng, G. (2026). Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide. JACC: Advances, 5(12), 103402. https://doi.org/10.1016/j.jacadv.2026.103402
Vancouver
Yan J, Zeng G. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide. JACC: Advances. 2026;5(12):103402. doi:10.1016/j.jacadv.2026.103402
BibTeX
@article{Yan2026,
author = {Yan, Jianghe and Zeng, Guangting},
title = {Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide},
journal = {JACC: Advances},
year = {2026},
volume = {5},
number = {12},
pages = {103402},
doi = {10.1016/j.jacadv.2026.103402}
}
EUVIMED